Answers are grounded in this paper and cite their sources.
Randomized trial evaluates safety and effectiveness of amyloid medications in dementia, indicating no significant cognitive benefits.
Are amyloid-targeting monoclonal antibodies safe and effective for mild cognitive impairment (MCI) or Alzheimer disease? Randomized controlled trials (RCTs) of monoclonal antibodies for patients with dementia or MCI found no clinically meaningful improvements in cognitive scores. These medications
No takes yet. Share an insight, caveat, or question.
Kolber et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: